Clinical Trials Browser

Phase 2/3 × Completed × osimertinib × Clear all

NCT02959749 2018-02-14

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Phase 2/3 Completed

Progression Free Survival